Air-in-Line Alarms During Antineoplastic Drug Infusion
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Routine Infusion Technologies.
- Кому может быть актуально
- Состояния в реестре: Infusion Safety, Medication Safety, Antineoplastic Drug Administration, Air-in-Line Alarm. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Италия
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Innovation in Antineoplastic Drug Infusion: A Multiphase Observational Study of Air-in-Line Alarms, Safety, and Therapeutic Continuity
Обзор
The goal of this observational study is to evaluate infusion alarms, particularly air-in-line alarms, during antineoplastic drug infusion in oncology care settings. The main questions it aims to answer are: How frequently do infusion alarms occur, and what types of alarms are observed during antineoplastic drug infusion? How long does it take healthcare professionals to manage infusion alarms and restore infusion continuity? What strategies do healthcare professionals use to manage infusion alarms? How do healthcare professionals evaluate the user experience of different infusion technologies? Participants will be healthcare professionals involved in antineoplastic drug infusion. They will not receive any experimental intervention. Researchers will observe routine infusion procedures and collect data on alarm events, alarm management, infusion technologies, and user experience.
Подробное описание
ntravenous administration of antineoplastic drugs represents a complex and high-risk clinical process. Antineoplastic agents are classified as high-alert medications because administration errors may lead to severe clinical consequences. One of the most relevant operational issues in infusion oncology practice is the occurrence of air-in-line alarms, which may interrupt drug administration, increase healthcare professionals' workload, and negatively affect therapeutic continuity. This issue may be particularly relevant with foaming drugs, which are more likely to generate microbubbles within infusion lines.
Despite the clinical relevance of infusion alarms, current literature does not provide robust real-world evidence regarding their prevalence, associated factors, or comparative performance of different infusion technologies in oncology settings. Furthermore, limited evidence is available regarding healthcare professionals' operational management of infusion alarms and user experience associated with infusion devices.
The present study is designed as a multicenter, prospective, observational, multiphase and multimethod study integrating three complementary methodological phases.
Phase 1 consists of a controlled preclinical simulation study using standardized foaming preparations and infusion systems to evaluate the occurrence of air-in-line alarms under simulated conditions.
Phase 2 consists of a prospective field observational study aimed at evaluating healthcare professionals' practices during antineoplastic drug infusion and infusion alarm management in real-world oncology settings. This phase applies the Entrustable Professional Activities framework to identify key professional competencies related to infusion safety and alarm management.
Phase 3 consists of a prospective multicenter observational cohort study aimed at collecting real-world data regarding infusion alarms, alarm management time, operational strategies, and healthcare professionals' user experience with infusion technologies routinely used in clinical practice.
The study does not include experimental interventions, treatment allocation, or modifications to standard clinical practice. All infusion technologies included in the study are CE-marked medical devices routinely used in participating centers according to their intended purpose. No patient clinical data will be collected. Data collection will focus on infusion-related technical events, organizational variables, observable professional behaviors, and healthcare professionals' user experience.
The study will be conducted in five Italian oncology centers and is expected to last approximately 24 months following ethics approval and local authorization procedures. Data will be collected and managed using the REDCap electronic data capture platform. Statistical analyses will include descriptive and inferential methods aimed at identifying factors associated with infusion alarm occurrence, alarm management, and user experience outcomes.
The results of this study are expected to contribute to the development of evidence-based recommendations for safer infusion practices, optimization of oncology infusion workflows, and improvement of healthcare professionals' training related to infusion technologies and alarm management.
Вмешательства
- Другое Routine Infusion Technologies
Observation of routinely used infusion technologies and infusion-related alarm management during standard antineoplastic drug administration in oncology care settings. No experimental intervention or treatment allocation is performed.
Первичные конечные точки
- Frequency and Type of Infusion Alarms [Срок оценки: Up to 24 months]
Вторичные конечные точки (6)
- Adherence to Evidence-Based Infusion Safety Practices [Срок оценки: Up to 24 months]
- User Experience With Infusion Technologies [Срок оценки: Up to 24 months]
- Operational Strategies for Infusion Alarm Management [Срок оценки: Up to 24 months]
- Alarm Management Time [Срок оценки: Up to 24 months]
- Inter-Center Variability in Alarm Management [Срок оценки: Up to 24 months]
- Factors Associated With Alarm Occurrence and Management [Срок оценки: Up to 24 months]
Критерии участия
Критерии включения
- Healthcare professionals involved in the administration of antineoplastic drugs in participating oncology centres.
- Employment in a participating study site during the study period.
- Direct involvement in routine intravenous antineoplastic drug infusion procedures.
- Participation in infusion procedures eligible for observation according to the study protocol.
Критерии исключения
- Healthcare professionals not directly involved in antineoplastic drug administration.
- Healthcare professionals working outside participating study sites.
- Temporary staff not routinely involved in infusion activities during the observation period.
- Refusal to participate in study activities where local regulations require participant notification.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Италия · 5 центров
- AUSL Parma — Parma
- Fondazione Policlinico Universitario A. Gemelli IRCCS — Rome
- ASST Lodi — Lodi
- IRCCS Ospedale San Raffaele — Milan
- IEO - Istituto Europeo di Oncologia — Milan
Идентификаторы
NCT: NCT07718711 · AIIAO-AIRINLINE-2026